TVM Capital
Venture capitalMunich · Seed–Late Stage · 6 people tracked
Also known as TVM CAPITAL GMBH · TVM Techno Venture Management GmbH
Investment thesis
TVM Capital Life Science pursues a two-pronged investment strategy. First, it finances innovative early-stage therapeutics using a single-asset company approach, leveraging a strategic relationship with Eli Lilly and Company. Second, it invests in differentiated commercial-stage medtech, diagnostics, and digital health products, as well as late-stage therapeutics. The firm aims to develop and market products with the potential to transform medical practice and improve outcomes for patients and the healthcare system, while building value for its investors. It emphasizes strong support for its portfolio companies.
Source: firm website, verified Aug 3, 2026.
Team · 6 people
from the firm's website & curated & public directories
What they invest in
from 4 of 7 portfolio companiesBiotech ×3Healthtech ×2Medical Devices ×2Hardware ×1New Materials ×1
HQs:United States×4
Investments · 7 tracked
founders shown can be your intro pathBy year:2021 · 12017 · 12015 · 13 dated
Access Vascular develops thrombus-evading intravascular catheters made from a proprietary biomaterial, offering an FDA-cleared PICC and the HydroMID peripherally inserted midline catheter to reduce vascular access complications.
BiotechHealthtechMedical DevicesNew MaterialsBedford, US
James Biggins(Chief Executive Officer, President and Founder)Dennis Byrne(Chief Commercial Officer)Scott Blood(VP of Regulatory and Quality)Katie Motherway(VP of Human Resources)Paul Sabin(Director)Joseph Pellegrino(Director)
Board seatLuc Marengere· per SEC Form D
Co-investorsTVM Capital Life ScienceGreen Park & Golf Ventures
BiotechCambridge, US
Christopher Schelling(Executive Officer, Director, Promoter)Harry S. Palmin(Executive Officer, Director, Promoter)
BoardCynthia Lavoie(Director)
Board seatHubert Birner· per SEC Form D · $15.7M raise · filed Oct 2017
BiotechDurham, US
Bernice Kuca(Executive Officer)Mathers P. Thomas(Executive Officer, Director)Nadia Rupniak(Executive Officer)Timothy C. Gupton(Executive Officer)
BoardJesse I. Treu(Director)inRichard J. Markham(Director)
Board seatLuc Marengere· per SEC Form D · $37.1M raise · filed Jan 2015
Co-investorsPappas CapitalDomain Associates
Developer of an oral small molecule targeting a mutation involved in acute myeloid leukemia, sarcomas, and gliomas; acquired by Eli Lilly.
Project-focused company developing an aurora kinase A inhibitor (AK-01) licensed from Lilly; acquired by Lilly ~1.5 years after TVM's investment.
Developer of lasmiditan, an oral 5-HT1F agonist for acute migraine treatment; IPO'd on Nasdaq and later acquired by Lilly for $960 million.
Egg Medical develops the EggNest, a scatter radiation shielding system designed to reduce radiation exposure for interventional fluoroscopy teams during cardiac catheterization and endovascular procedures.
HardwareHealthtechMedical DevicesArden Hills, US
Robert F. Wilson(Founder & Chief Executive Officer)inJohn Gainor(Co-founder & Chief Technology Officer)inScott Youngstrom(Chief Financial Officer)inGavin Philipps(Chief Commercial Officer)in
BoardMarc Riviere(Director)Luc Marengere(Director)
Co-investorsJStar Capital InvestmentsTVM Capital Life Science
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 3
IPOs and acquisitions across the tracked portfolioAcanthasacq. by Eli LillyAurka Pharmaacq. by LillyCoLucidacq. by Lilly
Portfolio news
latest coverage across their companies
Egg Medical · intelligence360.news · Jul 20, 2026
Public market activity · per SEC filings
what is this? ⓘDisclosed stake · filed Mar 2011
Disclosed stake · filed Feb 2008
10 insider ownership filings (Forms 3/4/5)
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- How many investments has TVM Capital made?
- TVM Capital has 5 tracked investments, 3 of which have exited via acquisition or IPO.
- What stage does TVM Capital invest at?
- TVM Capital invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What is TVM Capital's typical check size?
- TVM Capital typically writes checks of $1.1M – $16.2M.
- What sectors does TVM Capital focus on?
- TVM Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is TVM Capital located?
- TVM Capital is headquartered in Munich, DE.
- Does TVM Capital lead rounds?
- Yes, TVM Capital leads investment rounds.
Media · Podcasts & interviews
featuring the teamBIO-Europe 2025: Interview with Dr. Hubert Birner from TVM Capital Life Science
MC Services AG · Hubert Birner
Bob Wilson, EGG Medical & Luc Marengere, TVM Capital Life Science - Studio Interview | LSI USA ‘24
LSI - Life Science Intelligence™ · Luc Marengere
BIO-Europe Spring 2024: Interview with Hubert Birner from TVM Capital Life Science
MC Services AG · Hubert Birner
BIO-Europe 2023: Interview with Hubert Birner of TVM Capital
MC Services AG · Hubert Birner
Where is the Money Going in Biotech? - Hubert Birner, Managing Partner at TVM Capital
Labiotech.eu · Hubert Birner
Images
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.